News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Insider Information

Ad Hoc: Epigenomics AG increases share capital

PDF 58 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that the Company’s Executive Board today with the approval of the Supervisory Board has resolved on an increase of the Company’s share capital by up to EUR 4,136,720 from the authorized capital. This capital increase follows a previous capital increase, published via ad […]

Read more

Ad hoc: Epigenomics and BioChain sign agreement for broad strategic collaboration in China

PDF 43 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that it has signed an agreement with BioChain regarding a broad strategic collaboration of both companies. BioChain is a leading clinical diagnostics company in cancer and genetic tests in China and the US. As part of the agreed collaboration, which significantly expands the […]

Read more

Ad hoc: Epigenomics issues new shares to BioChain – Investment follows agreement on broad strategic collaboration in China

PDF 39 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that BioChain and certain of its shareholders will invest US$ 1.3 million (EUR 0.94 million) into the Company by subscribing 217,935 newly issued shares. This investment follows the signing of an agreement regarding a broad strategic collaboration of both companies announced today. Executive […]

Read more

Ad hoc: Epigenomics signs joint commercialization agreement for Epi proColon® in North America with Polymedco

PDF 37 KB   Berlin, Germany– Epigenomics AG (ISIN: DE000A1K0516) announces that it has entered into a joint commercialization agreement with Polymedco Inc. Both companies will jointly commercialize Epi proColon®, Epigenomics’ blood-based test for colorectal cancer (CRC) screening, in North America. Under the terms of the agreement, Polymedco will deploy its CRC dedicated sales force […]

Read more

Epigenomics AG issues EUR 500,000 in convertible bonds to YA Global Master SPV Ltd.

PDF 84 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516, OTC: EPGNY) announces that upon registration of the conditional capital of the Company today successfully completed the issuance of convertible bonds with a nominal amount of EUR 500,000. These convertible bonds constitute the first tranche of a total issuance of up to EUR 5m […]

Read more

Ad hoc: Epigenomics AG secures financing of up to EUR 5m

PDF 80 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that it has entered into an agreement with YA Global Master SPV Ltd. through which it secured a convertible bond financing for up to EUR 5m. Under the terms of the agreement, YA Global Master SPV Ltd., over a period of up to […]

Read more